Fig. 2.

Disease activity during the first and second courses of treatment as measured by a DAS28-ESR, b DAS28-CRP, c CDAI and d SDAI (efficacy population). Efficacy population for the first course included 100 patients in the CT-P10 and 48 patients in the innovator rituximab treatment groups. Of these, 82 patients received a second course of treatment (59 and 23 patients in the CT-P10 and innovator rituximab treatment groups, respectively). CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score using 28 joints, ESR erythrocyte sedimentation rate, RTX innovator rituximab, SD standard deviation, SDAI Simplified Disease Activity Index